Squamous Cell Carcinoma News and Research RSS Feed - Squamous Cell Carcinoma News and Research

Squamous Cell Carcinoma is cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. Also called epidermoid carcinoma.
TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). [More]
Scientists find link between makeup of individual's microbiome and head and neck cancer

Scientists find link between makeup of individual's microbiome and head and neck cancer

In a sample study, researchers at Johns Hopkins say they have found an association between the makeup of an individual's microbiome and head and neck cancer, a finding that potentially advances the quest for faster and more accurate cancer diagnosis and therapy. [More]
Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial. [More]
AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016. [More]
Loyola researchers detect tumor gene that may help predict survival outcomes in mouth cancer patients

Loyola researchers detect tumor gene that may help predict survival outcomes in mouth cancer patients

Loyola researchers have identified a tumor gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [More]
First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab. [More]
Molecular basis for tongue cancer progression: an interview with Dr Simona Principe

Molecular basis for tongue cancer progression: an interview with Dr Simona Principe

Head and neck cancers (HNC) are the sixth most common cancers worldwide, with approximately 600,000 new cases diagnosed every year. [More]
Combination drug therapy may stop KRAS-mediated lung adenocarcinoma

Combination drug therapy may stop KRAS-mediated lung adenocarcinoma

Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent. [More]
Diets high in glycemic index linked to increased risk of lung cancer

Diets high in glycemic index linked to increased risk of lung cancer

Consuming a diet with a high glycemic index, a classification of how rapidly carbohydrates elevate blood sugar levels, was independently associated with an increased risk of developing lung cancer in non-Hispanic whites, according to a new epidemiologic study from The University of Texas MD Anderson Cancer Center. [More]
P. gingivalis could be a novel risk factor for esophageal cancer

P. gingivalis could be a novel risk factor for esophageal cancer

University of Louisville School of Dentistry researchers have found a bacterial species responsible for gum disease, Porphyromonas gingivalis, is present in 61 percent of patients with esophageal squamous cell carcinoma (ESCC). [More]
New clinical trial launched to test potential drug that could help immune system combat cancer

New clinical trial launched to test potential drug that could help immune system combat cancer

Cancer Research UK's Centre for Drug Development, in partnership with Amgen Inc., has launched a new clinical trial to test a drug that could stop a patient's immune system from protecting tumours. [More]
Researchers examine molecular profile of HPV-positive oropharyngeal squamous cell carcinoma

Researchers examine molecular profile of HPV-positive oropharyngeal squamous cell carcinoma

Throat cancer patients exposed to both human papillomavirus (HPV) and tobacco smoke demonstrate a pattern of mutations along several key cancer genes, according to research presented today at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Post-treatment imaging can help detect recurrences of HPV-positive oropharyngeal cancer

Post-treatment imaging can help detect recurrences of HPV-positive oropharyngeal cancer

For patients treated with definitive radiation therapy (RT) for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at three months and physical exams during the six months following treatment, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Induction chemotherapy fails to improve survival in head and neck cancer patients

Induction chemotherapy fails to improve survival in head and neck cancer patients

Head and neck cancer patients who receive chemotherapy prior to radiation therapy (induction chemotherapy or IC) rather than the standard treatment that combines chemotherapy with radiation (chemoradiation or CRT) show no survival benefit and are less likely to receive a full course of radiation, according to research from the University of Colorado Cancer Center presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Uninsured and Medicaid patients have higher overall and cancer-specific mortality rates

Uninsured and Medicaid patients have higher overall and cancer-specific mortality rates

Compared to patients with non-Medicaid insurance, uninsured patients and patients with Medicaid are more likely to present with advanced stages of head and neck cancer and have higher overall and cancer-specific mortality rates, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
Chemoradiation improves survival rates among subset of elderly head and neck cancer patients

Chemoradiation improves survival rates among subset of elderly head and neck cancer patients

The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity scores and advanced disease stage, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium. [More]
DEK gene present in plasma can help predict outcomes for patients with head and neck cancer

DEK gene present in plasma can help predict outcomes for patients with head and neck cancer

Researchers at the University of Cincinnati have discovered that a human cancer-causing gene, called DEK, can be detected in the plasma of head and neck cancer patients. DEK may help doctors understand how a person's immune system could be used to treat cancer or predict outcomes for patients. [More]
Anti-TNF therapy linked to ‘modest’ extra SCC risk

Anti-TNF therapy linked to ‘modest’ extra SCC risk

A Swedish population-based study shows that treatment with tumour necrosis factor inhibitors significantly increases the risk of developing squamous cell carcinoma, but not basal cell carcinoma, in patients with rheumatoid arthritis. [More]
Advertisement
Advertisement